The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for certain activity generated through this link. Prices displayed are informational.

Headquartered in Pleasanton, California, Veeva Systems Inc. (VEEV) is a cloud software company serving the life sciences industry. With a market capitalization of $38.7 billion, the company provides solutions for clinical trials, customer management, regulatory compliance, data, quality, and commercial operations.

Shares of this leading life sciences software company have significantly underperformed the broader market over the past year. VEEV has plunged 14% over this period, while the broader S&P 500 Index ($SPX) has climbed nearly 19.3%. The stock has also underperformed in 2026, rising 8.7% year-to-date, compared to the index's 12.4% gain. 

Barron Trump, 20, Now Worth $150 Million — More Than Mom, Melania — From Crypto And $39 Energy Drink

Billionaire Michael Saylor Warns Against Buying a House Because 'Every 36 Years You Actually Pay the Cost of the House in Tax to the Government'

QQQ Just 'Gamma Flipped' as Market Makers Were Forced to Sell. Here's What Our Top Chart Expert is Tracking Next.

Stop Missing Market Moves: Get the FREE Barchart Brief – your midday dose of stock movers, trending sectors, and actionable trade ideas, delivered right to your inbox. Sign Up Now!

Compared with the State Street Health Care Select Sector SPDR ETF (XLV), VEEV has also underperformed, as the ETF has advanced 24.9% over the past year and gained 9.6% year-to-date.

Veeva Systems has underperformed the broader market amid concerns over softer demand and competitive pressures. Although Veeva maintained a strong 28.8% average operating margin and 49.4% free cash flow margin over the past year, Q1 billings came in at $850 million, while year-over-year billings growth averaged 13% over the past four quarters, slightly lagging the software sector. The weaker billings performance raised concerns about increasing competition and challenges in acquiring and retaining customers.

Analysts expect VEEV's diluted EPS to increase 13.5% year-over-year to $6.65 for the fiscal year ending in January 2027. VEEV has surpassed consensus EPS estimates in three of the past four quarters, while missing expectations in one quarter.

Based on the 27 analysts covering VEEV stock, the consensus rating is a "Moderate Buy." The rating is based on 15 "Strong Buys," three "Moderate Buys," eight "Holds," and one "Strong Sell."

The configuration is more bullish than it was a month ago, when the stock had 14 "Strong Buy" ratings.

On August 17, Oppenheimer analyst Ken Wong maintained an Outperform rating on Veeva Systems and raised the price target from $225 to $300. Wong cited improving software sentiment and resilience in vertical SaaS despite budget pressures and lengthening sales cycles.

Based on analysts' estimates, the mean price target of $247.16 implies a 1.8% premium to VEEV's current share price, while the Street-high price target of $340 suggests a 40.1% upside.

On the date of publication, Kritika Sarmah did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. This article was originally published on Barchart.com